

DAFTAR PUSTAKA

1. PP PERKI. Panduan Tata Laksana Penyakit Kardiovaskular Pada Kehamilan. I. Ann A, Anna S, Rahajoe U, Surwianti P, Antonia R, Lukito A, et al., editors. 2021. 1,6.
2. Sirait A. Prevalensi Hipertensi Pada Kehamilan Di Indonesia Dan Berbagai Faktor Yang Berhubungan (Riset Kesehatan Dasar 2007). Buletin Penelitian Sistem Kesehatan. 2013;15(2):103–9.
3. WHO. Maternal mortality Evidence Brief [Internet]. Maternal mortality. 2019. p. 1–4. Available from: <https://apps.who.int/iris/bitstream/handle/10665/329886/WHO-RHR-19.20-eng.pdf?ua=1>
4. Khosravi S, Dabiran S, Lotfi M, Asnavandy M. Study of the Prevalence of Hypertension and Complications of Hypertensive Disorders in Pregnancy. *Open J Prev Med*. 2014;04(11):860–7.
5. Safitri A, Djaiman SPH. Hubungan Hipertensi dalam Kehamilan dengan Kelahiran Prematur: Metaanalisis. *Media Penelitian dan Pengembangan Kesehatan*. 2021;31 No. 1:27–38.
6. Mudjari NS, Samsu N. Management of Hypertension in Pregnancy. *Acta Medica Indonesia - Indonesia J Intern Med*. 2015;47 No.1:78–86.
7. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J*. 2018;39(6):3021–104.
8. Ratnapalan S, Koren G. Taking ACE inhibitors during pregnancy. Is it safe? *Can Fam Physician [Internet]*. 2002 [cited 2022 Feb 22];48(JUNE.):1047–9. Available from: [/pmc/articles/PMC2214066/?report=abstract](https://pubmed.ncbi.nlm.nih.gov/1214066/)
9. Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, et al. Major Congenital Malformations after First-Trimester Exposure to ACE Inhibitors. *N Engl J Med [Internet]*. 2009 Oct 8 [cited 2022 Feb 22];354(23):2443–51. Available from: <https://www.nejm.org/doi/full/10.1056/nejmoa055202>
10. Quan A. Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. *Early Hum Dev*. 2006;82(1):23–8.
11. Herman LL, Padala SA, Ahmed I, Bashir K. Angiotensin Converting Enzyme Inhibitors (ACEI) [Internet]. StatPearls Publishing; 2021 [cited 2022 Feb 24]. p. <https://www.ncbi.nlm.nih.gov/books/NBK431051/>. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK431051/>
12. Singh KN, Singh G. Teratogenic effect of ace inhibitor (lisinopril) and chrysanthemum indicum(Guldaudi) on head and face region of mice fetuses. *J Anat Soc India [Internet]*. 2011;60(2):181–3. Available from:

[http://dx.doi.org/10.1016/S0003-2778\(11\)80021-3](http://dx.doi.org/10.1016/S0003-2778(11)80021-3)

13. Keilman C, Shanks AL. Oligohydramnios - StatPearls - NCBI Bookshelf [Internet]. StatPearls Publishing. 2021 [cited 2022 Mar 7]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK562326/>
14. Fikri AM, Sulaeman A, Handharyani E, Marliyati SA, Fahrudin M. The effect of propolis administration on fetal development. *Heliyon* [Internet]. 2019;5(10):1–7. Available from: <https://doi.org/10.1016/j.heliyon.2019.e02672>
15. Ahmed SS, Sultana N, Begum ML, Lima LS, Abedin MF, Hosen MK. Pregnancy Induced Hypertension and Associated Factors among Pregnant Women. *J Gynecol Womens Heal*. 2017;3(4).
16. Sibai BM. Diagnosis and Management of Gestational Hypertension and Preeclampsia. *Am Coll Obstet Gynecol*. 2003;102(1):181–92.
17. Wang W, Xie X, Yuan T, Wang Y, Zhao F, Zhou Z, et al. Epidemiological trends of maternal hypertensive disorders of pregnancy at the global, regional, and national levels: a population-based study. *BMC Pregnancy Childbirth*. 2021;21(1):1–10.
18. Luger RK, Kight BP. Hypertension In Pregnancy [Internet]. Vol. 6, *Nephrologie et Therapeutique*. StatPearls Publishing; 2021 [cited 2022 Feb 24]. p. 200–14. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK430839/>
19. Braunthal S, Brateanu A. Hypertension in pregnancy: Pathophysiology and treatment. *SAGE Open Med*. 2019;7:1–15.
20. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. *Eur Heart J*. 2018;39(34):3165–241.
21. Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Rouse DJ, Spong CY. *William Obstetrics*. 23th ed. McGraw-Hill Medical; 2010. 725 p.
22. (KBBI) KBBI. Arti kata nulipara - [Internet]. [cited 2022 Feb 23]. Available from: <https://kbbi.web.id/nulipara>
23. Hinkosa L, Tamene A, Gebeyehu N. Risk factors associated with hypertensive disorders in pregnancy in Nekemte referral Hospital, from July 2015 to June 2017, Ethiopia: case control study. *BMC Pregnancy Childbirth*. 2020;20(16):1–9.
24. Skjærven R, Vatten LJ, Wilcox AJ, Rønning T, Irgens LM, Lie RT. Recurrence of pre-eclampsia across generations: Exploring fetal and maternal genetic components in a population based cohort. *Br Med J*. 2005;331(7521):877–9.
25. Shen M, Smith GN, Rodger M, White RR, Walker MC, Wen SW. Comparison of risk factors and outcomes of gestational hypertension and

- pre-eclampsia. PLoS One. 2017;12(4):1–13.
26. Fox NS, Hill MB, Connolly CT, Klahr RA, Zafman KB, Rebarber A. The association between high-normal blood pressure and the development of preeclampsia in twin pregnancies. *J Matern Neonatal Med* [Internet]. 2019;1–5. Available from: <https://doi.org/10.1080/14767058.2019.1601696>
 27. Gestational Hypertension [Internet]. Stanford Children’s Health. [cited 2022 Mar 2]. Available from: <https://www.stanfordchildrens.org/en/topic/default?id=gestational-hypertension-90-P02484>
 28. Wallace K, Spencer S-K. Hypertension During Pregnancy: A Link to Post-Partum Depression and Anxiety? [Internet]. Vol. 10, *Journal of Gynecology and Women’s Health*. Juniper Publishers; 2018 [cited 2022 Feb 22]. p. 1–4. Available from: <http://juniperpublishers.com/jgwh/JGWH.MS.ID.555795.php>
 29. Hladunewich M, Karumanchi SA, Lafayette RA. Pathophysiology of the clinical manifestations of preeclampsia. *Clin J Am Soc Nephrol*. 2007;2(3):543–9.
 30. Genatha DW. The Relationship Between Depression and Hypertension Incident in Pregnant Women. *J Berk Epidemiol*. 2018;6(3):209–18.
 31. American College of Obstetricians, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy [Internet]. Vol. 122, *Obstetrics and gynecology*. *Obstet Gynecol*; 2013 [cited 2022 Feb 23]. p. 1122–31. Available from: <https://pubmed.ncbi.nlm.nih.gov/24150027/>
 32. Espinoza J, Vidaeff A, Pettker christian m, Simhan H. Gestational Hypertension and Preeclampsia - Clinical Management Guidelines for Obstetrician – Gynecologists. *Obstet Gynecol*. 2020;135(6):237–60.
 33. Magley M, Hinson MR. Eclampsia [Internet]. StatPearls. StatPearls Publishing; 2022 [cited 2022 Feb 24]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK554392/>
 34. Leeman L, Dresang LT, Fontaine P. Hypertensive Disorders of Pregnancy. *Am Acad Fam Physician*. 2016;93(2).
 35. Langtry HD, Markham A. Lisinopril. A review of its pharmacology and clinical efficacy in elderly patients. *Drugs Aging* [Internet]. 1997 [cited 2022 Feb 25];10(2):131–66. Available from: <https://pubmed.ncbi.nlm.nih.gov/9061270/>
 36. Lopez EO, Parmar M, Pendela VS, Terrell JM. Lisinopril [Internet]. xPharm: The Comprehensive Pharmacology Reference. StatPearls Publishing; 2022 [cited 2022 Feb 25]. p. 1–5. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK482230/>

37. Zisaki A, Miskovic L, Hatzimanikatis V. Antihypertensive Drugs Metabolism: An Update to Pharmacokinetic Profiles and Computational Approaches. *Curr Pharm Des.* 2015;21(6):806–22.
38. Messerli FH, Bangalore S, Bavishi C, Rimoldi SF. Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use? *J Am Coll Cardiol* [Internet]. 2018;71(13):1474–82. Available from: <https://doi.org/10.1016/j.jacc.2018.01.058>
39. Alldredge BK, Corelli RL, Ernst ME, Guglielmo BJ, Jacobson PA, Kradjan WA, et al. *Koda-Kimble & Young's Applied Therapeutics The Clinical Use of Drugs.* 10th ed. Troy DB, editor. LIPPINCOTT WILLIAMS & WILKINS; 2013. 1–2561 p.
40. Bezalel S, Mahlab-Guri K, Asher I, Werner B, Sthoeger ZM. Angiotensin-converting enzyme inhibitor-induced angioedema. *Am J Med* [Internet]. 2015;128(2):120–5. Available from: <http://dx.doi.org/10.1016/j.amjmed.2014.07.011>
41. Goa KL, Balfour JA, Zuanetti G. Lisinopril : A review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction. *Drugs Eval.* 1996;52(4):564–88.
42. Lancaster SG, Todd PA. Lisinopril A Preliminary Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Hypertension and Congestive Heart Failure. 1988;35(6):646–69.
43. Papich MG. Lisinopril. In: *Saunders Handbook of Veterinary Drugs (Fourth Edition)* [Internet]. 4th ed. Elsevier; 2016. p. 454–5. Available from: <https://www.sciencedirect.com/science/article/pii/B9780323244855003417>
44. Laurent S. Antihypertensive drugs. *Pharmacol Res* [Internet]. 2017;124:116–25. Available from: <http://dx.doi.org/10.1016/j.phrs.2017.07.026>
45. Matveev A V., Egorova EA, Matveeva N V., Krashennnikov AE, Dormidor AG. Adverse reactions of ace inhibitors. Retrospective analysis of spontaneous reports in local database. *New Armen Med J.* 2019;13(2):10–7.
46. Wagh VD. Propolis : A Wonder Bees Product and Its Pharmacological Potentials. *Adv Pharmacol Sci.* 2013;1–11.
47. Anjum SI, Ullah A, Khan KA, Attaullah M, Khan H, Ali H, et al. Composition and functional properties of propolis (bee glue): A review. *Saudi J Biol Sci* [Internet]. 2019;26(7):1695–703. Available from: <https://doi.org/10.1016/j.sjbs.2018.08.013>
48. Braakhuis A. Evidence on the health benefits of supplemental propolis. *Nutrients.* 2019;11.
49. Lotfy M. Biological activity of bee propolis in health and disease. *Asian Pacific J Cancer Prev.* 2006;7(1):22–31.
50. Dillasamola D, Almahdy A, Sari NP, Putri BO, Noverial, Diliarosta S.

- Evaluation of Propolis and Milk Administration on Caffeine-Induced *Mus musculus* Fetus Skeletal. *Pharm Sci Res.* 2018;5(1):40–8.
51. Kocot J, Kielczykowska M, Luchowska-Kocot D, Kurzepa J, Musik I. Antioxidant potential of propolis, bee pollen, and royal jelly: Possible medical application. *Oxid Med Cell Longev.* 2018;2018:1–29.
 52. Mutsaers M, Blitterswijk H van, Leven L van't, Kerkvliet J, Waerdt J van de. *Bee Products Properties, Processing and Marketing.* 1st ed. Agromisa Foundation; 2005.
 53. Kumazawa S, Hamasaka T, Nakayama T. Antioxidant activity of propolis of various geographic origins. *Food Chem.* 2004;84(3):329–39.
 54. Banskota AH, Tezuka Y, Adnyana IK, Ishii E, Midorikawa K, Matsushige K, et al. Hepatoprotective and anti-*Helicobacter pylori* activities of constituents from Brazilian propolis. *Phytomedicine.* 2001;8(1):16–23.
 55. Seifer R. Teratology. In: *Encyclopedia of Infant and Early Childhood Development.* Academic Press; 2008. p. 333–43.
 56. Mulyani T, Ida Julianti C, Sihombing R. Tinjauan Pustaka: Teknik Pengujian Toksisitas Teratogenik Pada Obat Herbal. *J Farm Udayana.* 2020;9(1):31–6.
 57. Finnell RH. Teratology: General considerations and principles. *J Allergy Clin Immunol.* 1999;103:1–5.
 58. Coady MA, Bower S. *Twining's Textbook of Fetal Abnormalities.* 3rd ed. Homfray T, Farndon PA, editors. Churchill Livingstone Elsevier; 2015. 140–141,160 p.
 59. BPOM. PerKB POM Republik Indonesia No.7 Tahun 2014 Pedoman Uji Toksisitas Nonklinis Secara In Vivo. Badan Pengawas Obat Dan Makanan Republik Indonesia. Badan Pengawas Obat Dan Makanan Republik Indonesia; 2014. p. 66–8.
 60. Byers SL, Wiles M V., Dunn SL, Taft RA. Mouse estrous cycle identification tool and images. *PLoS One.* 2012;7(4):1–5.
 61. Sharma C, Vani V, Jayamma Y, Inamdar LS. Estrous Cycle in Rodents: Phases, Characteristics and Neuroendocrine regulation. *Karnatak Univ J Sci.* 2020;51(December):40–53.
 62. Huda NK, Sumarmin R, Ahda Y. PENGARUH EKSTRAK SAMBILOTO (*Andrographis paniculata* Nees.) TERHADAP SIKLUS ESTRUS MENCIT (*Mus musculus* L. Swiss Webster). *EKSAKTA Berk Ilm Bid MIPA.* 2017;18(02):69–76.
 63. Bahri S, Irmayani I, Aulia J, Lathifah MF, Adawiyah R. Efek Estrogenik Ekstrak Buah Tomat (*Lycopersicon esculentum*) Terhadap Mencit Betina Dewasa (*Mus musculus*) Galur Balb/C. *J Pijar Mipa.* 2021;16(2):222–7.
 64. Hayes AW. *Principles and Method of Toxicology.* 4th ed. New York: Taylor

& Francis Routledge Pleum Press; 2001.

65. A A. Teratologi Eksperimental. Padang: Andalas University Press; 2012.
66. Sadler TW. Langman's Medical Embryology. 9th ed. Montana The Magazine Of Western History. LIPPINCOTT WILLIAMS & WILKINS; 2003.
67. Setyawati I. Morfologi Fetus Mencit (*Mus musculus L.*) Setelah Pemberian Ekstrak Daun Sambiloto (*Andrographis paniculata Nees*). J Biol [Internet]. 2009;13(2):41–4. Available from: <http://ojs.unud.ac.id/index.php/BIO/article/view/583/386>
68. Fitton CA, Fleming M, Steiner MFC, Aucott L, Pell JP, MacKay DF, et al. In Utero Antihypertensive Medication Exposure and Neonatal Outcomes: A Data Linkage Cohort Study. Hypertension. 2020;628–33.
69. Ekeuku SO, Chin KY. Application of propolis in protecting skeletal and periodontal health—a systematic review. Molecules. 2021;26(11).
70. Armutcu F, Akyol S, Ustunsoy S, Turan FF. Therapeutic potential of caffeic acid phenethyl ester and its anti-inflammatory and immunomodulatory effects (Review). Exp Ther Med. 2015;9(5):1582–8.

